Day: July 30, 2023

Apellis Provides Update on Review of Rare Safety Events with SYFOVRE® (pegcetacoplan injection) for Geographic Atrophy

Staff July 30, 2023

No indication that drug product or manufacturing issues contributed to rare events of retinal vasculitisConfirmed seven total events of non-occlusive/occlusive...

Aflibercept 8 mg Two-Year Results from Pivotal PHOTON Trial in Diabetic Macular Edema Presented at ASRS

Staff July 30, 2023

89% and 84% of patients were maintained on ≥12- and ≥16-week dosing intervals, respectively, throughout the two-year period, while sustaining their...

4DMT Presents Additional Positive Interim Data from Intravitreal 4D-150 Phase 1/2 PRISM Clinical Trial in Patients with Wet AMD at ASRS 2023

Staff July 30, 2023

4D-150 clinical efficacy endpoints for evaluable patients in all three cohorts (n=14) at 36 weeks Table for 4D-150 clinical efficacy...

Day: July 30, 2023

Apellis Provides Update on Review of Rare Safety Events with SYFOVRE® (pegcetacoplan injection) for Geographic Atrophy

Aflibercept 8 mg Two-Year Results from Pivotal PHOTON Trial in Diabetic Macular Edema Presented at ASRS

4DMT Presents Additional Positive Interim Data from Intravitreal 4D-150 Phase 1/2 PRISM Clinical Trial in Patients with Wet AMD at ASRS 2023

Fortitude Wellbeing Enhances Mental Health Services with Comprehensive ADHD Assessments

MedMira receives Health Canada approval for its Multiplo(R) Rapid (TP/HIV) Test for Syphilis and HIV

Mexico’s EHR Revolution: Driving Digital Health Innovation and Market Growth, Insights From Black Book Research

Rapid Dose Announces Proposed Issuance of Shares as Payment of Director Fees

Trinity Biotech Announces Amended Credit Agreement with Perceptive to Enhance Liquidity and Drive Transformation Plan

You may have missed